Pharmaceutical major Lupin has lost â‚¹3,315 crore from its market valuation in just two days. Lupin shares plunged by 3% during intraday trade on Wednesday after US health regulators issued observations for its plant. The observations were made in Form 483, which are made when investigators feel practices are such that products may become adulterated or render injuries to health.